BioXcel Therapeutics, Inc. Effective Income Tax Rate Reconciliation, Nondeductible Expense, Other, Amount
BioXcel Therapeutics, Inc. (BTAI) reported Effective Income Tax Rate Reconciliation, Nondeductible Expense, Other, Amount of $420.00 thousand for the 12-month period ending 2025-12-31, per its 10-K filed 2026-03-27.
Financial Statements › Expense Statement › Income Tax
us-gaap:IncomeTaxReconciliationNondeductibleExpenseOther · last filed 2026-03-27
- BioXcel Therapeutics, Inc. effective income tax rate reconciliation, nondeductible expense, other, amount for fiscal 2025 was $420.00K, a 15.49% decline from fiscal 2024.
- BioXcel Therapeutics, Inc. effective income tax rate reconciliation, nondeductible expense, other, amount for fiscal 2024 was $497.00K.
| Period end | Effective Income Tax Rate Reconciliation, Nondeductible Expense, Other, Amount 12 month |
|---|---|
| 2025-12-31 | $420.00K 10-K · filed 2026-03-27 |
| 2024-12-31 | $497.00K 10-K · filed 2026-03-27 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| JUPITER NEUROSCIENCES, INC. (JUNS) | United States | $0.002B | -0.02 |
| ORAGENICS INC (OGEN) | United States | $0.002B | |
| ZyVersa Therapeutics, Inc. (ZVSA) | United States | $0.002B | |
| Nexentis Technologies Inc. (NXTS) | $0.002B | ||
| Decoy Therapeutics Inc. (DCOY) | United States | $0.002B | -0.27 |
| Matinas BioPharma Holdings, Inc. (MTNB) | United States | $0.003B | |
| Petros Pharmaceuticals, Inc. (PTPI) | United States | $0.003B | |
| GeoVax Labs, Inc. (GOVX) | United States | $0.003B | -0.45 |
| Silo Pharma, Inc. (SILO) | United States | $0.003B | -1.57 |
| Genprex, Inc. (GNPX) | United States | $0.003B | -0.02 |